Currently, Heron Therapeutics Inc [HRTX] is trading at $1.63, saw in change for the day. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HRTX shares have gain 10.88% over the last week, with a monthly amount glided 3.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Heron Therapeutics Inc [NASDAQ: HRTX] stock has seen the most recent analyst activity on June 13, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $7. Previously, CapitalOne started tracking the stock with Overweight rating on April 23, 2024, and set its price target to $6. On March 13, 2024, Needham reiterated its Buy rating and revised its price target to $5 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $24 on May 27, 2020. Needham reiterated its recommendation of a Buy and reduced its price target to $48 on February 20, 2020. Needham reiterated a Buy rating for this stock on January 16, 2019, and downed its price target to $64. In a note dated April 05, 2018, Evercore ISI initiated an Outperform rating and provided a target price of $56 on this stock.
This stock has fluctuated between a low of $1.04 and a high of $3.93 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Heron Therapeutics Inc [NASDAQ: HRTX] shares were valued at $1.63 at the most recent close of the market. An investor can expect a potential return of 329.45% based on the average HRTX price forecast.
Analyzing the HRTX fundamentals
Trailing Twelve Months sales for Heron Therapeutics Inc [NASDAQ:HRTX] were 137.74M which represents 4.38% growth. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.19%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is 0.77 and Total Capital is -0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5950 points at the first support level, and at 1.5600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6600, and for the 2nd resistance point, it is at 1.6900.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Heron Therapeutics Inc [NASDAQ:HRTX] is 2.28. Also, the Quick Ratio is 1.74, while the Cash Ratio stands at 0.3. Considering the valuation of this stock, the price to sales ratio is 1.80.
